ScreenerHero

TVTX Travere Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · travere.com
52.04USD-2.62%Mkt Cap: 4.84B $P/E: —

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap4.84B USD
Enterprise Value5.40B USD
Revenue (TTM)591.33M USD
Gross Profit480.39M USD
Net Income (TTM)-25.55M USD
Revenue/Share6.48 USD
Last Price52.04 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees497
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)9.87
PEG—
EV/EBITDA235.87
EV/Revenue9.14
P/S8.80
P/B215.31
EPS (TTM)-0.74
EPS (Forward)5.67
52W Range
22.0564% of range68.73
52W High68.73 USD
52W Low22.05 USD
Profitability
Gross Margin97.89%
Oper. Margin2.33%
EBITDA Margin3.88%
Profit Margin-5.21%
ROE-22.25%
ROA-4.22%
Growth
Revenue Growth48.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF37.78M USD
CapEx (TTM)58.16M USD
FCF Margin-3.09%
FCF Yield-0.38%
Net Debt127.73M USD
Net Debt/EBITDA5.57
Balance Sheet
Debt/Equity2.86
Current Ratio4.05
Quick Ratio3.76
Book Value/Sh0.26 USD
Cash/Share5.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)75.21 USD
Upside (mean)+44.5%
Target Range62.00 USD – 90.00 USD
62.00+44.5% to mean90.00
# Analysts14
Ownership
Shares Out.92.99M
Float93.22M
Insiders0.69%
Institutions115.10%
Short Interest
Short Ratio10.2d
Short % Float17.90%
Short % Out.13.74%
Shares Short12.96M
Short (prev mo.)11.94M
Technical
SMA 5062.26 (-16.4%)
SMA 20045.11 (+15.4%)
Beta1.14
S&P 52W Chg16.45%
Avg Vol (30d)1.60M
Avg Vol (10d)1.89M
Technical Indicators
RSI (14)27.7
MACD-2.1879
MACD Signal-1.1190
MACD Hist.-1.0689
BB Upper69.28 USD
BB Middle60.53 USD
BB Lower51.78 USD
BB Width28.91%
ATR (14)2.568 USD
Vol Ratio (20d)0.93x